Molecular Interactions between NAFLD and Xenobiotic Metabolism
Open Access
- 1 January 2013
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 4, 38623
Abstract
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is a complex multifactorial disease characterized by metabolic deregulations that include accumulation of lipids in the liver, lipotoxicity, and insulin resistance. The progression of NAFLD to non-alcoholic steatohepatitis and cirrhosis, and ultimately to carcinomas, is governed by interplay of pro-inflammatory pathways, oxidative stress, as well as fibrogenic and apoptotic cues. As the liver is the major organ of biotransformation, deregulations in hepatic signaling pathways have effects on both, xenobiotic and endobiotic metabolism. Several major nuclear receptors involved in the transcription and regulation of phase I and II drug metabolizing enzymes and transporters also have endobiotic ligands including several lipids. Hence, hepatic lipid accumulation in steatosis and NAFLD, which leads to deregulated activation patterns of nuclear receptors, may result in altered drug metabolism capacity in NAFLD patients. On the other hand, genetic and association studies have indicated that a malfunction in drug metabolism can affect the prevalence and severity of NAFLD. This review focuses on the complex interplay between NAFLD pathogenesis and drug metabolism. A better understanding of these relationships is a prerequisite for developing improved drug dosing algorithms for the pharmacotherapy of patients with different stages of NAFLD.Keywords
This publication has 99 references indexed in Scilit:
- Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in ratsEuropean Journal of Pharmacology, 2009
- The Thrsp null mouse (Thrsptm1cnm) and diet-induced obesityMolecular and Cellular Endocrinology, 2009
- Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat DietThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Genome-wide profiling of PPARγ:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesisGenes & Development, 2008
- The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolismBMC Genomics, 2008
- Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2Toxicology and Applied Pharmacology, 2008
- Non-alcoholic fatty liver disease: The mist gradually clearsJournal of Hepatology, 2008
- The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitisGut, 2006
- Mutual repression between steroid and xenobiotic receptor and NF- B signaling pathways links xenobiotic metabolism and inflammationJournal of Clinical Investigation, 2006
- Peroxisome proliferator–activated receptor α mediates the adaptive response to fastingJournal of Clinical Investigation, 1999